A study was carried out to determine the cost effectiveness of a pharmacist in identifying possible drug-related problems (PDRPs) using three methods: chart reviews, rounding with physicians, and patient drug profiles. The clinical significance of the PDRPs was also determined.
Introduction
IN RECENT YEARS, the federal government and health professionals have recognized that drug-related problems are a major health problem. The final report of the Task Force on Prescription Drugs estimated that approximately three billion dollars are spent annually on the treatment of drug-related problems. 1 Several controlled studies have shown that many hospitalized patients suffer adverse reactions to drugs. 2 · 3 · 4 Schimmel 5 and Hoddinott' 1 have shown that 18 to 30 percent of hospitalized patients have a drug reaction. As a consequence, the duration of hospitalization of these patients is increased. 4 · 5 - 6 Other investigators have found less than one percent adverse drug reactions in their population. 7 Adverse drug reactions are becoming recognized as a major health problem.
Carr's study shows that the average medical student in his four years of training receives an average of only 31 hours training in clinical pharmacology and applied therapeutics. 8 The nursing education programs usually have only one formal pharmacology course in their curriculum. While physicians and nurses are adequately trained for their individual needs in this area, pharmacists by virtue of their specialized knowledge of drug actions are better able to handle drug-related problems. The colleges of pharmacy curriculums have included several courses concerned with drug-related problems. One emphasis of these drug-related courses is to educate While the colleges of pharmacy and the federal government have emphasized the education of clinical pharmacists, hospital pharmacies, nursing homes and retail pharmacies have been reluctant to hire them. Despite federal monies being spent on the development of persons to perform these professional functions, there is very little in the literature to document the cost and effectiveness of pharmacists in identifying or solving drug-related problems. A search of the literature has revealed very little with one exception concerning the cost and effectiveness of pharmacists identifying drugrelated problems. A recent study addressed itself to the problems of determining the incidence of potential drug interactions and to estimate the time and cost involved in monitoring therapy. 9 The patients were monitored for drug interactions by screening their drug profiles and reviewing their charts. A seven percent incidence of drug interactions for the inpatient population at this hospital was found. The cost of monitoring drug profiles per patient day was four cents and the cost per interaction detected was approximately four dollars. This study did not address itself to the problem of determining effectiveness of a pharmacist in detecting drug interactions or determining the superiority of one method of identifying drug interaction over another.
The purpose of this study was to determine the relative effectiveness of a pharmacist and the cost involved in identifying possible drug-related problems (PDRPs) using three methods: rounding with physicians; reviewing patient charts; and checking patient drug profiles.
Defiinitions
The word possible is defined as "that which may be true or a fact, or may perhaps be the case, as something concerning that which one has no knowledge to the contrary." 10 Since the clinical significance of drug-related problems identified were not established, the word possible was used to describe the drug-related problems (PDRP). Each PDRP was documented by using Drug Interactions, 11 Evaluations of Drug Interactions, 12 and Hazards of Medication. 13 
Design of Study
The institution used was a 140-bed hospital that treated approximately 60,000 patients a year. Fifty-six thousand patients were treated in outpatient specialty clinics, and 4000 were admitted for inpatient treatment. The average patient stay for 1973 was 10.2 days. The population is made up of Mexican-Americans, Indians, Blacks, and Caucasians. The inpatient services were divided into medical and surgical and included a neuropsychiatrie service, urology, orthopedics, chest, gynecology, DEFINITIONS A possible drug-disease interaction occurred when an order of a drug which was contraindicated in a patient with a certain disease state was written, e.g., an order for a cold remedy which contains sympathomimetic amines for a diabetic patient.
A possible drug-drug interaction was any therapeutic incompatibility caused by taking two drugs at the same time which have potentiating, inhibiting, or opposing effect, e.g., the potentiating effect of phenylbutazone in a patient currently on coumadin therapy.
A possible drug-food interaction was considered to be caused by taking a drug and food into the body at the same time and was manifested by an altered effect of the drug in the patient, e.g., the decreased effectiveness of tetracycline when given with meals.
A possible drug-hypersensitivity (allergic) reaction was any adverse reaction of a patient to a drug whose symptoms were related to the individual's increased immunologie response to the drug, e.g., an anaphylactic reaction to a dose of penicillin.
A possible dosage regimen error occurred when the dosage regimen differed significantly from that listed in the literature accompanying the drug, e.g., a five-day course of therapy of ampicillin suspension instead of the recommended ten-day course of therapy.
A possible drug toxicity was any pharmacologie action of a drug that is exaggerated due to an overdose. neurosurgery, ear, nose and throat, opthalmology, and radiotherapy. Therefore, this was considered to be representative of a small general hospital. This study was conducted on the medical wards which has 34 beds. The population of patients on this ward were adult males and females who were usually ill both acutely and subacutely. Most had multiple disease states. There were few elective admissions on this ward.
An expert panel consisting of a professor from the College of Pharmacy, a teaching physician, and a pharmacist (hereafter referred to as the investigator) was formed to identify PDRPs. The expert panel was expected to identify a majority of the PDRPs of the patient population.
To determine if a drug-related problem was clinically significant, the investigator reviewed the charts of all patients identified as having a PDRP. If the physicians noted an adverse effect in the patient's chart and the treatment was discontinued, the PDRP was determined to be clinically significant (CSDRP) based upon the attending physician's judgment.
Methodology
During this six-month study, the investigator and expert panel examined 50 percent of the patient medical charts on the medical ward. The charts were examined every day at approximately the same time, and the time spent reading the charts and looking for PDRPs in texts on hand was recorded in minutes for each patient. The charts examined were for the patients in even-numbered beds so a cross section of the male and female patients was obtained. The time spent looking for charts and the time lost due to interruptions while reviewing patient charts was not included. The PDRPs found were not brought to the attention of the physicians and interns as the purpose of the study was to identify, not solve, PDRPs. Also, if all the PDRPs were discussed with physicians when detected, this would have altered the prescribing techniques and skills of the physicians.
The second method used in this study was rounding with physicians. Here the investigator attended work rounds with the attending physician, the resident physician, the medical intern and the nurse. It was explained to the physicians that the investigator was collecting data for experimental purposes which necessitated his keeping a time card. The investigator assumed a passive observing role and did not initiate any discussion concerning 
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Furosemide-Penicillin Allergy Eighteen other single incident problems patient therapy. The other members of the expert panel rounded with physicians on the same day and followed the same patients, but did not round with the investigator. If either the investigator or the other members of the expert panel received information concerning a PDRP from another panel member, the results of that patient were dropped from the study. The investigator was free to converse with the patients and consult the chart at bedside as a reference. The investigator did not study the chart for extended periods of time as he might during the review of patient charts. The last method used in detecting PDRPs was the checking of patient drug profiles. A patient drug profile system was already in use in the hospital's pharmacy. The system was adequate except that it lacked an active problem list for the patient. Therefore, an active problem list was added to the profile system and this modified patient drug profile system was used (Figure 1) . The time spent using this method was recorded only while monitoring the patient drug profile and did not include the time spent in preparation or maintenance of profiles.
The time spent identifying PDRPs using the three methods described was recorded in minutes on a time card. The time card was designed to include the date, time in and out, and the patient's name and was used to record the time spent with each patient while rounding, reviewing patient charts, and monitoring drug profiles.
Patients were followed using a problem-oriented approach. A card designed for this purpose was termed a SOAP card. This patient information card included subjective patient information (e.g., signs and symptoms), objective patient information (e.g., diagnostic examination results), assessment of the patient's condition, plan for treatment (medications or other therapy), and a list of the patient's active problems (Figure 2 ). Each PDRP identified by the investigator was recorded on the reverse side of the SOAP card. It contained the date, PDRP and evidence, and references (Figure 3 ).
Results and Discussion
A total of 243 PDRPs were detected and documented utilizing rounding with physicians, chart review, and patient drug profiles. A total of 224 separate patients were studied and 124 (55.4 percent) were found to have PDRPs. Of the 124 patients with PDRPs, the investigator examined 105 charts to determine the number of clinically significant drug-related problems (CSDRPs). The 19 remaining charts of the patients with PDRPs were not available for review. The PDRPs were subdivided into six categories: drug-drug interaction, drugfood interaction, drug-disease interaction, drug toxicity, drug allergy, and dosage regimen error. The most frequent PDRP detected was the drug-drug interaction which accounted for 71.6 percent of the PDRPs found, however, only 1.1 percent were clinically significant ( Table 1 ). The least frequent PDRP identified was drug-food interaction which only accounted for 0.4 percent of the PDRPs identified and was not found to be clinically significant. Although drug allergies only accounted for 2.9 percent of the PDRPs, they were found to be 100 percent clinically significant. Almost twelve percent of the PDRPs were categorized as drug toxicities. Twenty-one of these 29 (72.4 percent) were clinically significant. Table 2 shows the 12 most common PDRPs discovered. Of the 243 PDRPs, 13 were identified as antacid-penicillin, 12 were digitalis toxicities, and 10 were antacidiron. The most frequently involved drug was digitalis which made up 15.6 percent of all PDRPs detected. The next most frequently involved drug was an antacid which constituted 15.2 percent of all PDRPs identified. These two drugs made up nearly 31 percent of the PDRPs found.
Digitalis toxicities accounted for 25.7 percent of the CSDRPs (Table 3) . Table 4 shows the percentage of patients with PDRPs. While 20.1 percent had three or more PDRPs, 44.6 percent of the patients had no PDRPs.
The investigator was most effective in identifying PDRPs using the patient drug profile system (Table 5) . However, only 5.0 percent of those PDRPs were significant ( Table 6 ). The investigator was least efficient in identifying PDRPs using the rounding the physicians method but most effective in detecting CSDRPs. The chart review method of identifying drug-related problems was in between the aforementioned methods in detecting both possible and clinically significant drug-related methods. The cost per PDRP identified by the investigator was $5.38 utilizing $6.40 as the average hourly wage for a pharmacist at the hospital (Table 7) . Table 7 shows the patient drug profiles as the least expensive method for detecting PDRPs. However, only six of the 102 PDRPs were clinically significant. Although rounding with physicians was the most expensive method of identifying PDRPs, 13 of 58 PDRPs (22.4 percent) were clinically significant ( Table 6 ).
Summary
Although rounding with physicians was the most expensive method for detecting PDRPs and the investigator was the least productive in detecting PDRPs, this method produced the highest percentage (22.4) of clinically significant drug-related problems. This method of identifying possible drug-related problems was the most effective and practical for several reasons. First, the rapport established with the members of the physician teams served as a strong motivating force. Second, rounding with the physician team was an educational experience and helped keep the investigator abreast of current trends in drug therapy. This increased the pharmacist effectiveness in monitoring drug therapy. Third, while doing chart review and patient drug profiles, PDRPs that had already occurred were detected. For the purposes of this study, the investigator while rounding with physicians did not affect drug prescribing habits. However, by rounding with physicians, the pharmacist has the chance to prevent PDRPs before they occur by discussing the drug therapy with the physician when the order is being written. As a result, this method would permit the pharmacist the most opportunity to affect physician drug prescribing habits. This team effort in prescribing drug therapy regimens maximizes the effectiveness of patient chemotherapy.
Chart review was a satisfactory method for detecting both possible and clinically significant drug related problems. The investigator was 56.1 percent effective in using the method for screening for PDRPs and 19.9 percent of the PDRPs were clinically significant.
The investigator, however, discovered that the method of chart review had some deficiencies. First, the physician did not always include a reason in the chart notes for prescriptions written for the patient. Second, there was an inadequate description of the patient's complaints and daily progress in the nurses' notes.
The patient drug profile system of detecting PDRPs was the best screening method of the three used in the study for detecting PDRPs. This method, however, was only 5.0 percent effective in identifying CSDRPs. The method of reviewing patient drug profiles had the drawbacks of having only a limited amount of information available on the patient profile and an absence of contact with the patient and the physician. Monitoring patient drug profiles was a tedious procedure and lacked the motivating force that the rounding with physicians method of identifying had. Therefore, the patient drug profile method requires close supervision to keep it updated and productive.
For the pharmacist who is considering the implementation of a method for screening for PDRPs, the findings of this research would indicate the utilization of the rounding with physicians system. Although rounding with physicians was found to be more expensive, the pharmacist would have a greater opportunity to affect patient care due to the greater number of CSDRPs identified. It is important that the pharmacist become an integral part of the patient care team. This cannot be done in the pharmacy simply by reviewing patient drug profiles.
During the period of this study, the average patient day stay on the medical wards was 10.2 days and the average cost per patient day was $101. Twenty-eight patients (11.6 percent) studied experienced one or more CSDRPs. If each patient who had CSDRPs had an extended hospital stay of only two days, the increased hospital cost due to adverse drug reactions for the affected population would be $5,656. This added expense due to the adverse drug reaction can be compared to the cost of identifying a PDRP by the methods used in this study. The pharmacist is able to detect drug-related problems at a reasonable cost and, therefore, can provide needed services as well as a product in our health care system.
